(Q33391089)

English

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study (English)

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

Krishna V Komanduri

object named as

Krishna Komanduri

6

0 references

Guillermo Garcia-Manero

10

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

16 December 2017

PMC publication ID

2

object named as

Sergio Giralt

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

Richard E Champlin

9

object named as

Richard Champlin

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

3

object named as

Peter F Thall

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

Leandro de Padua Silva

4

object named as

Leandro de Padua Silva

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

5

object named as

Roy B Jones

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

author name string

Marcos de Lima

1

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

Thomas M Braun

7

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

Hoang Q Nguyen

8

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

language of work or name

0 references

publication date

29 July 2010

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

116

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

23

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

5420-5431

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Second hematopoietic stem cell transplantation in myeloid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5669059

21 June 2018

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

21 January 2018

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20672358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simultaneously optimizing dose and schedule of a new cytotoxic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/20672358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Decitabine and sickle cell disease: molecular therapy for a molecular disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20672358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/20672358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/20672358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modern Applied Statistics with S

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25500

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25500

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 December 2017

http://europepmc.org/abstract/PMC/5669059

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33391089&oldid=1977381186"